Thus, aggressive HG bladder cancers are characterized by elevated NUAK2 expression and YAP/TAZ activity, and either blocking expression or pharmacologically inhibiting NUAK2 is effective in restoring Hippo pathway activity and attenuating cell growth. Here, NUAK2 is linked to urinary bladder cancer.